Notice2021-20268
Findings of Research Misconduct
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 20, 2021
Issuing agencies
Health and Human Services Department
Abstract
Findings of research misconduct have been made against Ya Wang, M.D., Ph.D. (Respondent), retired Professor and Director, Division of Experimental Radiation Oncology, Department of Radiation Oncology, Winship Cancer Institute, Emory University (EU). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Cancer Institute (NCI), National Institutes of Health (NIH), grants P30 CA138292 and R01 CA186129 and National Institute of General Medical Sciences (NIGMS), NIH, grant R01 GM080771. The administrative actions, including debarment for a period of four (4) years, were implemented beginning on August 4, 2021, and are detailed below.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 179 (Monday, September 20, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 179 (Monday, September 20, 2021)]
[Notices]
[Pages 52158-52160]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-20268]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Ya
Wang, M.D., Ph.D. (Respondent), retired Professor and Director,
Division of Experimental Radiation Oncology, Department of Radiation
Oncology, Winship Cancer Institute, Emory University (EU). Respondent
engaged in research misconduct in research supported by U.S. Public
Health Service (PHS) funds, specifically National Cancer Institute
(NCI), National Institutes of Health (NIH), grants P30 CA138292 and R01
CA186129 and National Institute of General Medical Sciences (NIGMS),
NIH, grant R01 GM080771. The administrative actions, including
debarment for a period of four (4) years, were implemented beginning on
August 4, 2021, and are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr. P.H., Acting
Director, Office of Research Integrity,
[[Page 52159]]
1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Ya Wang, M.D., Ph.D., Emory University: Based on the report of an
inquiry conducted by EU and analysis conducted by ORI in its oversight
review, ORI found that Dr. Ya Wang, retired Professor and Director,
Division of Experimental Radiation Oncology, Department of Radiation
Oncology, Winship Cancer Institute, EU, engaged in research misconduct
in research supported by PHS funds, specifically NCI, NIH, grants P30
CA138292 and R01 CA186129 and NIGMS, NIH, grant R01 GM080771.
Respondent neither admits nor denies ORI's findings of research
misconduct. The settlement is not an admission of liability on the part
of the Respondent. The parties entered into a Voluntary Exclusion
Agreement to conclude this matter without further expenditure of time,
finances, or other resources.
ORI found that Respondent engaged in research misconduct by
knowingly, intentionally, and/or recklessly falsifying data that were
included in the following one (1) PHS grant application and six (6)
published papers:
<bullet> R21 HL154577-01, ``GPRC5A Inhibits Error-Prone Repair to
Maintain Lung Genomic Integrity,'' submitted to the National Heart,
Lung, and Blood Institute (NHLBI), NIH, on December 13, 2019.
<bullet> miR-21-Mediated Radioresistance Occurs via Promoting
Repair of DNA Double Strand Breaks. J Biol Chem. 2017 Feb
24;292(8):3531-40; doi: 10.1074/jbc.M116.772392 (hereafter referred to
as ``J Biol Chem. 2017''). Retraction in: J Biol Chem. 2020 May
1;295(18):6250; doi: 10.1074/jbc.W120.013725.
<bullet> Distinct Roles of Ape1 Protein, an Enzyme Involved in DNA
Repair, in High or Low Linear Energy Transfer Ionizing Radiation-
Induced Cell Killing. J Biol Chem. 2014 Oct 31; 289(44):30635-44; doi:
10.1074/jbc.M114.604959 (hereafter referred to as ``J Biol Chem.
2014''). Retraction in: J Biol Chem. 2020 May 1;295(18):6249; doi:
10.1074/jbc.W120.013724.
<bullet> OCT4 as a Target of miR-34a Stimulates p63 but Inhibits
p53 to Promote Human Cell Transformation. Cell Death Dis. 2014 Jan
23;5(1):e1024; doi: 10.1038/cddis.2013.563 (hereafter referred to as
``Cell Death Dis. 2014'').
<bullet> MicroRNA-21 Modulates the Levels of Reactive Oxygen
Species by Targeting SOD3 and TNF[alpha]. Cancer Res. 2012 Sep
15;72(18):4707-13; doi: 10.1158/0008-5472.CAN-12-0639 (hereafter
referred to as ``Cancer Res. 2012a'').
<bullet> RNAi-Mediated Targeting of Noncoding and Coding Sequences
in DNA Repair Gene Messages Efficiently Radiosensitizes Human Tumor
Cells. Cancer Res. 2012 Mar 1; 72(5):1221-8; doi: 10.1158/0008-
5472.CAN-11-2785 (hereafter referred to as ``Cancer Res. 2012b'').
<bullet> Over-Expression of miR-100 is Responsible for the Low-
Expression of ATM in the Human Glioma Cell Line: M059J. DNA Repair
(Amst). 2010 Nov 10;9(11):1170-5; doi: 10.1016/j.dnarep.2010.08.007
(hereafter referred to as ``DNA Repair 2010'').
ORI found that respondent knowingly, intentionally, and/or
recklessly falsified protein immunoblot data by reusing and relabeling
the same images to represent different experimental conditions in
mammalian tissue culture models of DNA damage and repair in eighteen
(18) figure panels in eleven (11) figures in one (1) grant application
and six (6) published papers.
Specifically:
<bullet> Western blot images for total protein expression in
distinct transgenic mouse cell lines were falsified by reusing
immunoblot bands and relabeling them to represent different experiments
in eleven (11) figure panels in two (2) papers, including:
--Figure 3D in J Biol Chem. 2017, representing [beta]-actin expression
(left side panel) in wildtype (WT), microRNA-21 (miR-21) knock-in, and
miR-21<SUP>-/-</SUP> mouse embryonic fibroblast (MEF) cells exposed to
irradiation
--Figure 4C in J Biol Chem. 2017, representing DNA-PKcs expression in
miR-21 knock-in MEF cells exposed to irradiation
--Figure 5A in J Biol Chem. 2017, representing CDC25A and [beta]-actin
expression in WT, GSK3B<SUP>-/-</SUP>, and Cyclin D1<SUP>-/-</SUP> MEF
cells transfected with control or gene-specific silencing RNA (siRNA)
--Figure 1 in J Biol Chem. 2014, representing [beta]-actin expression
in Ku80<SUP>-/-</SUP> (Figure 1A) and Ogg1<SUP>-/-</SUP> (Figure 1C)
MEF cells transfected with expression or control vectors
--Figure 3 in J Biol Chem. 2014, representing H2A expression in WT MEF
(Figure 3A), Ku80<SUP>-/-</SUP> MEF (Figure 3B), Ogg1<SUP>-/-</SUP> MEF
(Figure 3C), and Ogg1\+\ (rescue) MEF (Figure 3D) cells transfected
with expression or control vectors and in the absence or presence of
radiation exposure
--Figure 3D in J Biol Chem. 2014, representing Mre11 (left panel)
expression in Ogg1\+\ (rescue) MEF cells transfected with expression or
control vectors in the absence or presence of radiation exposure
--Figure 4B in J Biol Chem. 2014, representing Mre11 expression in
Ogg1<SUP>-/-</SUP> MEF cells with control or Ape1 expression vector in
the presence of low or high linear energy transfer (LET) irradiation
--Figure 5C in J Biol Chem. 2014, representing Ape1 and [beta]-actin
expression in WT MEF cells with or without gene depletion and
transfected with control or various Ape1 expression vectors
<bullet> western blot images for total protein expression in human
cell lines subject to gene depletion and/or overexpression were
falsified by reusing immunoblot bands and relabeling them to represent
different experiments in seven (7) figure panels in five (5) papers and
one (1) grant application, including:
--Figure 4A in NIH grant application R21 HL154577-01, representing
GPRC5A levels in different patient-derived cell lines with gene
suppression or depletion
--Figure 4D in J Biol Chem. 2017, representing total DNA-PKcs,
phosphorylated DNA-PKcs, CDC25A, and GSK3B levels in human embryonic
kidney cells transfected with controls or various expression vectors
and/or miR-21 mimics
--Figure 5C in J Biol Chem. 2017, representing CDC25A, GSK3B, Cyclin
D1, and [beta]-actin expression in human embryonic kidney cells with or
without gene depletion and transfected with controls or miR-21 mimics
--Figure 5B in Cell Death Dis. 2014, representing p53 and p63 levels in
human lung epithelial cells with or without gene depletion
--Figure 3A in Cancer Res. 2012a, representing TNF[alpha] levels in
control and miR-21 overexpressing human lung epithelial cells at
different time points following irradiation
--Figure 5A in Cancer Res. 2012b, representing XRCC4 levels in both
human lung and brain epithelial cells with gene depletion at multiple
time points and treated with or without an artificial microRNA
--Figure 3A in DNA Repair 2010, representing ATM and Ku70 levels in
human glioblastoma-derived cells with or without gene depletion
<bullet> western blot images for proteins from chromatin DNA
complexes in mouse cell lines transfected with control or expression
vectors and in the absence or presence of irradiation were falsified by
reusing immunoblot bands
[[Page 52160]]
and relabeling them to represent different experiments in three (3)
figure panels in one (1) paper, including:
--Figure 3 in J Biol Chem. 2014, representing chromatin-bound [gamma]-
H2AX levels in WT MEF (Figure 3A), Ogg1<SUP>-/-</SUP> MEF (Figure 3C),
and Ogg1\+\ (rescue) MEF (Figure 3D) cells transfected with a control
or expression vector and in the absence or presence of irradiation
Dr. Wang entered into a Voluntary Exclusion Agreement (Agreement)
and voluntarily agreed to the following:
(1) Respondent agreed to exclude herself voluntarily for a period
of four (4) years beginning on August 4, 2021, from any contracting or
subcontracting with any agency of the United States Government and from
eligibility for or involvement in nonprocurement programs of the United
States Government referred to as ``covered transactions'' pursuant to
HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on
Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively
the ``Debarment Regulations'').
(2) Respondent agreed to exclude herself voluntarily from serving
in any advisory capacity to PHS including, but not limited to, service
on any PHS advisory committee, board, and/or peer review committee, or
as a consultant for a period of four (4) years, beginning on August 4,
2021.
(3) As a condition of the Agreement, Respondent will request that
the following papers be corrected or retracted in accordance with 42
CFR 93.407(a)(1) and Sec. 93.411(b):
<bullet> Cell Death Dis. 2014 Jan;5(1):e1024
<bullet> Cancer Res. 2012 Sep 15;72(18):4707-13
<bullet> Cancer Res. 2012 Mar 1;72(5):1221-8
<bullet> DNA Repair (Amst). 2010 Nov 10;9(11):1170-5
Respondent will copy ORI and the Research Integrity Officer at EU
on the correspondence.
Dated: September 15, 2021.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2021-20268 Filed 9-17-21; 8:45 am]
BILLING CODE 4150-31-P
</pre></body>
</html>Indexed from Federal Register on September 20, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.